Technical Analysis for CASI - CASI Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 3.15 -2.17% -0.07
CASI closed down 2.17 percent on Friday, May 17, 2019, on 86 percent of normal volume. It ran into resistance at its 50 day moving average. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Earnings due: May 21

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical CASI trend table...

Date Alert Name Type % Chg
50 DMA Resistance Bearish 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Stochastic Reached Oversold Weakness 0.00%
BB Squeeze Ended Range Expansion 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
50 DMA Resistance Bearish -2.17%
Bollinger Band Squeeze Range Contraction -2.17%
NR7 Range Contraction -2.17%
Lower Bollinger Band Walk Weakness -2.17%

Older signals for CASI ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
CASI Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops therapeutics to treat cancer and other diseases primarily in the United States and China. The company's lead drug candidate includes ENMD-2076, an Aurora A and angiogenic kinase inhibitor for the treatment of cancer, which has completed Phase I studies in patients with advanced solid tumors, multiple myeloma, and leukemia, as well as it is completing data for a multi-center Phase II study in patients with platinum resistant ovarian cancer. Its other product candidates in development include 2-methoxyestrdiol, an orally active compound for autoimmune diseases; and MKC-1, an orally-active cell cycle inhibitor that has completed Phase II clinical trials for cancer treatment. The company name was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Rockville, Maryland.
Biotechnology Cancer Life Sciences Pharmaceutical Diseases Treatment Of Cancer Autoimmune Diseases Multiple Myeloma Cancer Treatment Leukemia Pyrrolidines Cyclacel Advanced Solid Tumors Pacritinib
Is CASI a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 8.89
52 Week Low 2.73
Average Volume 175,784
200-Day Moving Average 4.2304
50-Day Moving Average 3.2314
20-Day Moving Average 3.293
10-Day Moving Average 3.276
Average True Range 0.15
ADX 13.64
+DI 14.4558
-DI 18.6902
Chandelier Exit (Long, 3 ATRs ) 3.05
Chandelier Exit (Short, 3 ATRs ) 3.56
Upper Bollinger Band 3.4518
Lower Bollinger Band 3.1342
Percent B (%b) 0.05
BandWidth 9.644701
MACD Line -0.0142
MACD Signal Line 0.0065
MACD Histogram -0.0207
Fundamentals Value
Market Cap 189.62 Million
Num Shares 60.2 Million
EPS -0.13
Price-to-Earnings (P/E) Ratio -24.23
Price-to-Sales 0.00
Price-to-Book 7.28
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.32
Resistance 3 (R3) 3.33 3.28 3.29
Resistance 2 (R2) 3.28 3.24 3.28 3.28
Resistance 1 (R1) 3.22 3.22 3.20 3.21 3.27
Pivot Point 3.17 3.17 3.16 3.17 3.17
Support 1 (S1) 3.11 3.13 3.09 3.10 3.03
Support 2 (S2) 3.06 3.11 3.06 3.02
Support 3 (S3) 3.00 3.06 3.01
Support 4 (S4) 2.99